Comparison of Visual Fields: Humphrey Field Analyzer (HFA) SITA Strategy, SCOPE (GATE Strategy) and Humphrey MATRIX Perimeter

Detection of Visual Field Defects and Scotoma Progression in Glaucomatous Optic Neuropathy, Using Short-term Intervals With Automated Scotoma-oriented Perimetry (SCOPE) and the Fast Thresholding Strategy GATE (German Adaptive Threshold Estimation)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01068938

Acronym

X-SCOPE

Enrollment

Registered

2010-02-17

Start date

2008-11-30

Completion date

2016-12-31

Last updated

2016-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Keywords

visual field, perimetry, glaucoma progression, grid, POAG and glaucoma suspects with prostaglandin monotherapy

Brief summary

The purpose of this study is to compare three perimetric techniques regarding progression of the visual field.

Interventions

DEVICEthree different perimeters: HFA, Octopus, MATRIX

visual fields

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* max. ± 8 dpt sph, max. ± 3 dpt cyl * distant visual acuity \> 10/20 * isocoria, pupil diameter \> 3 mm * at least one risk of progression: optic disc (splinter) hemorrhage / cup to disc ratio (CDR) \> 0.7 / inter-eye asymmetry of CDR \>0.2 / notching of the optic disc /retinal nerve fibre layer (RNFL) defects / intraocular pressure( IOP) \>22 mmHg / central corneal thickness \< 520 µm / advanced visual field defect stage Aulhorn III / elder than 70 years

Exclusion criteria

* pregnancy, nursing * diabetic retinopathy * asthma * HIV+ or AIDS * history of epilepsy or significant psychiatric disease * medications known to effect visual field sensitivity * infections (e.g. keratitis, conjunctivitis, uveitis) * severe dry eyes * miotic drug * amblyopia * squint * nystagmus * albinism * any ocular pathology, in either eye, that may interfere with the ability to obtain visual fields,disc imaging or accurate IOP readings * keratoconus * intraocular surgery (except for uncomplicated cataract surgery) performed \< 3 month prior to screening * history or signs of any visual pathway affection other than glaucoma * allergies with regard to topic glaucoma medication * history or presence of macular disease and / or macular edema * ocular trauma * medications known to affect visual field sensitivity

Design outcomes

Primary

Measure	Time frame
glaucoma progression	6 month

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026